NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

生物相似藥的全球市場、技術 - 包含COVID-19的影響:至2028年的預測

Global Biosimilars - Market and Technology Forecast to 2028: COVID-19 included Market Forecasts by Product, by Region, by Manufacturing, Current Market Overview, Market Trends and Leading Company Profiles

出版商 Market Info Group 商品編碼 960537
出版日期 內容資訊 英文 256 Pages
商品交期: 最快1-2個工作天內
價格
生物相似藥的全球市場、技術 - 包含COVID-19的影響:至2028年的預測 Global Biosimilars - Market and Technology Forecast to 2028: COVID-19 included Market Forecasts by Product, by Region, by Manufacturing, Current Market Overview, Market Trends and Leading Company Profiles
出版日期: 2020年06月15日內容資訊: 英文 256 Pages
簡介

預計生物相似藥的全球綜合市場,至2028年擴大到1,100億美元。生物相似藥市場,預計以約12%的年複合成長率成長。

本報告提供全球生物相似藥市場相關調查分析,市場概要,技術趨勢,市場分析,機會分析,主要企業等相關的系統性資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 全球生物相似藥市場目前市場概要

第4章 全球生物相似藥的目前技術趨勢

第5章 市場區隔

  • 各產品
  • 各地區
  • 各製造

第6章 市場分析

  • 簡介
  • 波特的五力分析
  • PEST
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 課題
  • 各國分析
    • 美國
    • 加拿大
    • 法國
    • 德國
    • 西班牙
    • 葡萄牙
    • 丹麥
    • 荷蘭
    • 瑞典
    • 芬蘭
    • 英國
    • 瑞士
    • 義大利
    • 日本
    • 以色列
    • 土耳其
    • 澳洲
    • 中國
    • 馬來西亞
    • 巴西

第7章 全球生物相似藥市場預測:各產品

  • 簡介
  • 全球生物相似藥市場概要:各產品
  • 全球生物相似藥市場:各產品(各製造)
    • 胰島素
    • 干擾素
    • Etanercept
    • Infliximab
    • Rituximab
    • 升糖素
    • 抑鈣素

第8章 全球生物相似藥市場預測:各地區

  • 簡介
  • 全球生物相似藥市場概要:各地區
  • 全球生物相似藥市場:各地區(各產品)
    • 北美
    • 歐洲
    • 亞太地區
    • 中東
    • 其他地區

第9章 全球生物相似藥市場預測:各製造

  • 簡介
  • 全球生物相似藥市場概要:各製造
  • 全球生物相似藥市場:各製造(各適應症)
    • 內部
    • 受託

第10章 全球生物相似藥市場機會分析

第11章 全球生物相似藥市場基於事件的預測

  • 簡介
  • 事件預測要素
  • 全球市場
  • 基於事件的預測:情況1
  • 基於事件的預測:情況2

第12章 COVID-19的影響

第13章 結論、建議

第14章 企業簡介

第15章 關於Market Info Group

第16章 附錄

目錄
Product Code: MIG200896

Biosimilars have a very complex molecular structure and they have similar characteristics as compared to their reference medicine. Biosimilars are mainly used to derive known effective medicinal products that have an expired patent. They are highly reliant on data analysis and they go through high quality and safety standards similar to that of Biological medicines. Biologics have a range of therapeutics and diagnostics based on them for prevalent diseases, although the cost incurred during this treatment is very high. Therefore, Biosimilars is a cost-effective substitute for Biologics since it provides the same quality of treatment at a lower cost.

Since the Biosimilars market is growing popular with time, it is seen that increasing awareness has been the main driver for this market. Concerning application, Oncology has been another key driver for this market mainly due to widespread Cancer in different parts of the world. Some of the key market players include Pfizer (US), Sandoz (Germany), Biocon (India), Biogen (US), etc.

The increasing frequency of chronic diseases such as diabetes, cancer, others that can be treated with biosimilars is probable to boost the market growth. Moreover, the prevalence of health problems like diabetes which has a means of treatment via biosimilars also aids the market growth in this case. Based on the product, Recombinant non-glucosylated protein has the biggest market share.

The total Global Market for Biosimilars is estimated to have a value of USD 20 Billion in 2020 and the market is anticipated to grow to USD 110 Billion by 2028. The Biosimilars market is expected to grow at a CAGR of around 12 %. The market revenue generated in the year of 2019 was estimated to be around USD 8 Billion.

The market segmentation for this sector is done based on Region, Product, and Manufacturing. There are three major products present in this market including- Recombinant Peptides Market, Recombinant glycosylated market, and Recombinant Non-glucosylated market. Amongst the three, the Recombinant Non-glucosylated market constitutes up to 48% of the market. Segmentation based on manufacturing gives us In-house and Contract manufacturing. On the basis of region gives us North America, Europe, APAC, the Middle East, and ROW. APAC constitutes for about 25-30% of the market. The In-house market for this segment constitutes up to 65%.

Scope:

"The Global Biosimilars- Market and Technology Forecast to 2028" report focuses on key market trends between the forecast period from 2020 to 2028. The Biosimilars market in this report is segmented based on Region, Product, and Manufacturing. The study period is from 2018-2028

The report is aimed at:

  • The drivers, restraints, and challenges faced in this market have been discussed in detail within the report which gives a comprehensive analysis of the market.
  • The key technologies that can have an impact on shaping this market's growth have been discussed.
  • The competitors in the field both regionally and company-wise have been covered in this report
  • The applications of this field's products and leading competitors within the same have been discussed.
  • A strategic plan of the report has been provided using the key tools.
  • The opportunities within this market for expired patents have been discussed.
  • The market study period for this report ranges from 2019-2028

Segmentation covered in this Report:

The market is segmented based Region, Manufacturing Technique, and Product:

Region-Wise Segmentation:

  • North America
  • Europe
  • APAC
  • Middle East
  • ROW

By Manufacturing:

  • Contract Manufacturing
  • Inhouse Manufacturing

By Indication:

  • Offsite Treatment
  • Oncology
  • Chronic Disorder
  • Autoimmune Disease
  • Blood Disorders
  • Infectious Disease
  • Other Diseases

Country Analysis:

  • United States
  • Canada
  • France
  • Germany
  • Spain
  • Portugal
  • Denmark
  • Netherlands
  • Sweden
  • Finland
  • United Kingdom
  • Switzerland
  • Italy
  • Japan
  • Israel
  • Turkey
  • Australia
  • China
  • Malaysia
  • Brazil

Reasons to Buy:

  • The key trends which would impact the market during the forecast period, 2020-2028 have been identified within this report which could help new entrants develop a comprehensive view.
  • New players could use this report to study the impacts of the drivers, restraint, and challenges on the Biosimilars market.
  • A detailed discussion of the key technologies and their impact on the market has been provided in this report which could be of use to existing players wanting to study upcoming technologies within this sector.
  • The existing players in the market could benefit from this report through the comprehensive analysis provided for the strategies employed by the key market players. Therefore, they could use this report to develop strategies of their own in reference to the data provided.
  • The sales team of the Biosimilars market could use this report to develop new strategies' to approach their clients with the help of the data provided.

Who is this report aimed for:

  • Biosimilars Manufacturers: Can use his report to identify the potential markets for growth.
  • Biosimilars Therapeutic Markets: This particular market could adhere to the growing demand with the help of this report.
  • Financial Institutions: Can use this report to study the current market and evaluate investment strategies.
  • Governments, Associations, and Industrial Bodies: Could use this report to find scope for expansion of this field.
  • Sales Teams: They can make use of this report to understand the drivers of the market and use it while making sales.

Table of Contents

1 Introduction

  • 1.1 Objective
  • 1.2 Market definition
  • 1.3 Methodology
  • 1.4 Events based Forecast Scenario
  • 1.5 Who will benefit from this report
    • 1.5.1 Business Leaders & Business Developers
  • 1.6 Language
  • 1.7 Opportunity Alerts

2 Executive Summary

  • 2.1 Global Biosimilars Market Trends and Insights
  • 2.2 Major Findings
  • 2.3 Major Conclusions
  • 2.4 Important Tables and Graphs

3 Current Market Overview of the Global Biosimilars Market

4 Current Technology Trends in the Global Biosimilars

5 Market Segmentation

  • 5.1 By Product
  • 5.2 By Region
  • 5.3 By Manufacturing

6 Market Analysis

  • 6.1 Introduction
  • 6.2 Porter's 5 Forces Analysis
    • 6.2.1 Competitive Rivalry
    • 6.2.2 Supplier Power
    • 6.2.3 Buyer Power
    • 6.2.4 Threat of Substitution
    • 6.2.5 Threat of New Entry
  • 6.3 PEST
  • 6.4 Market Dynamics
    • 6.4.1 Drivers
    • 6.4.2 Restraints
    • 6.4.3 Challenges
  • 6.5 Country Analysis
    • 6.5.1 United States
    • 6.5.2 Canada
    • 6.5.3 France
    • 6.5.4 Germany
    • 6.5.5 Spain
    • 6.5.6 Portugal
    • 6.5.7 Denmark
    • 6.5.8 Netherlands
    • 6.5.9 Sweden
    • 6.5.10 Finland
    • 6.5.11 United Kingdom
    • 6.5.12 Switzerland
    • 6.5.13 Italy
    • 6.5.14 Japan
    • 6.5.15 Israel
    • 6.5.16 Turkey
    • 6.5.17 Australia
    • 6.5.18 China
    • 6.5.19 Malaysia
    • 6.5.20 Brazil

7 Forecast Global Biosimilars Market by Product to 2028

  • 7.1 Introduction
  • 7.2 Global Biosimilars Market by Product overview
  • 7.3 Global Biosimilars Market By Product (By Manufacturing)
    • 7.3.1 Insulin
    • 7.3.2 Interferon
    • 7.3.3 Etanercept
    • 7.3.4 Infliximab
    • 7.3.5 Rituximab
    • 7.3.6 Glucagon
    • 7.3.7 Calcitonin

8 Forecast Global Biosimilars Market by Region to 2028

  • 8.1 Introduction
  • 8.2 Global Biosimilars Market by Region overview
  • 8.3 Global Biosimilars Market By Region (By Product)
    • 8.3.1 North America
    • 8.3.2 Europe
    • 8.3.3 APAC
    • 8.3.4 Middle East
    • 8.3.5 Rest of the World

9 Forecast Global Biosimilars Market by Manufacturing to 2028

  • 9.1 Introduction
  • 9.2 Global Biosimilars Market by Manufacturing Overview
  • 9.3 Global Biosimilars Market By Manufacturing (By Indication)
    • 9.3.1 Inhouse
    • 9.3.2 Contract

10 Opportunity Analysis Global Biosimilars Market

11 Events based forecast for the Global Biosimilars Market to 2028

  • 11.1 Introduction
  • 11.2 Events forecast factors
  • 11.3 Global Market
  • 11.4 Events Based Forecast- Scenario 1
  • 11.5 Events Based Forecast- Scenario 2

12 Corona Impact

13 Conclusions and recommendations

14 Company Profiles

15 About Market Info Group

  • 15.1 General
  • 15.2 Contact us
  • 15.3 Disclaimer
  • 15.4 License information
    • 15.4.1 1-User PDF License
    • 15.4.2 5-User PDF License
    • 15.4.3 Site PDF License
    • 15.4.4 Enterprise PDF License

16 Appendices

  • 16.1 Companies Mentioned
  • 16.2 Abbreviations